Quest Diagnostics Inc (DGX)

Industry Diagnostics & Research

This stock can be held in an Investment ISA and an Investment Account

Sell

$174.67

Buy

$189.46

arrow-up$0.99 (+0.55%)

Prices updated at 13 Dec 2025, 00:44 EST

Prices minimum 15 mins delay

Prices in USD

Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. It provides diagnostics for insurers and healthcare information technology businesses.

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Diagnostics & Research

Chairman

Mr. James E. Davis

CEO

Mr. James E. Davis

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

56,000

Head office

500 Plaza Drive

Secaucus

United States

07094

+1 973 520-2700

Investor@QuestDiagnostics.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Michael E. Prevoznik Senior Vice President and General Counsel	0.55m
Mr. Robert B. Carter Independent Director	0.07m
Mr. Timothy M. Ring Lead Independent Director	0.17m
Mr. Timothy L. Main Independent Director	0.13m
Ms. Denise M. Morrison Independent Director	0.13m
Mr. Gary M. Pfeiffer Independent Director	0.15m
Mr. Patrick Plewman Senior Vice President, Diagnostic Services	-
Ms. Vicky B. Gregg Independent Director	0.13m
Ms. Catherine T. Doherty Executive Vice President, Regional Businesses	0.62m
Mr. James E. Davis Chairman of the Board, President and Chief Executive Officer	1.25m
Mr. Sam A. Samad Executive Vice President and Chief Financial Officer	0.67m
Dr. Luis A. Diaz, Jr,M.D. Independent Director	0.12m
Mr. Michael J. Deppe Senior Vice President, Corporate Controller and Chief Accounting Officer	-
Mr. Wright L. Lassiter, III Independent Director	0.12m
Ms. Tracey C. Doi Independent Director	0.12m
Mr. Mark Delaney Senior Vice President and Chief Commercial Officer	-
Mr. Karthik Kuppusamy Senior Vice President, Clinical Solutions	0.54m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	14,233,576
BlackRock Inc	10,002,035
JPMorgan Chase & Co	8,634,782
T. Rowe Price Associates, Inc.	7,005,990
T. Rowe Price	5,424,776

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
27 Nov 2024	-
27 Nov 2024	-
27 Nov 2024	-
27 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
28 Oct 2024	-
21 Oct 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.